Continuing their groundbreaking research to find cancer treatment solutions to those resistant to alkylation-based chemotherapy, DelMar Pharmaceuticals, Inc. ($DMPI) presented "The unique mechanism of action of dianhydrogalactitol (VAL-083) may provide a new treatment option for chemo-resistant cancers," at the American Association for Cancer Research (AACR) New Horizons in Cancer Research Conference: Bringing Cancer Discoveries to Patients in Shanghai, China. The data highlights the Company's recent research supporting VAL-083 as a chemotherapeutic agent in the treatment of a variety of cancers.
"Poor outcomes due to drug-resistance remains a significant unmet clinical challenge for many cancer patients. New agents are needed to address treatment-resistant cancers," stated Jeffrey Bacha, President and CEO of DelMar Pharmaceuticals. "Historical clinical data from the US National Cancer Institute (NCI), along with our own preclinical and clinical trial data, all support the activity of VAL-083 against a range of tumor types via a novel mechanism of action that we believe could provide improved treatment options for patients."
The presentation was summarized as follows:
● VAL-083 activity is independent of O6-methylguanine-DNA methyltransferase (MGMT) expression and overcomes temozolomide (TMZ)-resistance in GBM cell lines;
● VAL-083 overcomes cisplatin-resistance in ovarian cancer and NSCLC cell lines;
● VAL-083 overcomes tyrosine kinase inhibitor (TKI)-resistance in non-small cell lung cancer (NSCLC) cell lines, including H1975 with T790M mutation in EGFR;
● VAL-083 displays synergy and super-additivity with both cisplatin and oxaliplatin in NSCLC cell lines, including TKI-resistant cells in vitro and in vivo;
● VAL-083 activity is independent of p53 status than in comparison to platinum-based chemotherapy; and
● VAL-083 is active against pediatric brain tumors in vitro including high grade gliomas (HGG), GBM cancer stem cells and p53 mutated SHH medulloblastoma.
"The data presented today support expanded clinical use of VAL-083 under its current lung-cancer approval in China,” said Bacha, “and also serve as the basis for global development of VAL-083 in important cancer indications such as GBM, NSCLC and ovarian cancer."
A biopharmaceutical company focused on the development and commercialization of new cancer therapies, Del Mar has announced a number of promising breakthroughs with VAL-083 in 2015. Earlier this month, the company presented positive data in the treatment of non-small cell lung cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. A first-in-class, small-molecule chemotherapeutic, VAL-083 has proven to be safe and effective in treating various cancers in over 40 Phase I and II clinical studies. Currently, the anti-cancer drug is approved to treat chronic myelogenous leukemia lung cancer in China, and is currently undergoing clinical trials in the US.
Del Mar is leading the way to a cancer-free world. Their breakthrough drug and consistent positive results throughout various clinical trials is helping fill the devastating gaps in modern cancer treatments. "These data represent important steps toward realizing our vision,” said Bacha, “of leveraging historical clinical data with new research into the mechanism of VAL-083 to address modern unmet medical needs in the treatment of cancer."
Equities.com had the opportunity to interview Jeffrey Bacha, President and CEO of DelMar Pharmaceuticals. The interview can be watched here. For more information about DelMar Pharmaceuticals, visit www.delmarpharma.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer